Please wait while the formulary information is being retrieved.
YESCARTA (AXICABTAGENE CILOLEUCEL)
- Diffuse large b-cell lymphoma
intravenous suspension
- Dosage information is not available
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Reactivation of hepatitis B
Contraindicated
- Hepatitis B immune due to latent hepatitis B infection
- Leukoencephalopathy
- Pregnancy
- Severe infection
Severe
Moderate
- Pancytopenia
YESCARTA (AXICABTAGENE CILOLEUCEL)
- Diffuse large b-cell lymphoma
- Cardiac arrhythmia
- Cytokine release syndrome
- Encephalopathy
- Hypoxia
- Infection
- Tachycardia
- Anorexia
- Chills
- Constipation
- Cough
- Diarrhea
- Dizziness
- Fatigue
- Fever
- Headache disorder
- Hypotension
- Nausea
- Tremor
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Hypertension
- Hypogammaglobulinemia
- Kidney disease with reduction in GFR
- Neutropenic disorder
- Thrombocytopenic disorder
- Thrombotic disorder
- Aphasia
- Arthralgias
- Back pain
- Dehydration
- Delirium
- Edema
- Insomnia
- Muscle spasm
- Muscle weakness
- Myalgias
- Pain
- Symptoms of anxiety
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Capillary leak syndrome
- Cardiac arrest
- Fungal infection
- Heart failure
- Hemophagocytic lymphohistiocytosis
- Hypersensitivity drug reaction
- Leukoencephalopathy
- Pleural effusions
- Pulmonary edema
- Seizure disorder
- Thrombophilia
Less Severe
- Acalculia
- Ataxia
- Myoclonus
- Skin rash
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Axicabtagene ciloleucel
No pediatric safety and efficacy.
- 1 Day – 18 Years
- No pediatric safety and efficacy.
Axicabtagene Ciloleucel
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Axicabtagene Ciloleucel
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Axicabtagene Ciloleucel
General-There is limited data regarding use in elderly. Risk for cytokine release syndrome (CRS). Cardiovascular-Use extreme caution in pre-existing CAD, heart failure and dysrhythmias due to CRS. Renal-Use extreme caution in CKD due to CRS. Neuro/Psych-Monitor for encephalopathy, delirium, etc. Pulmonary-CRS may impact COPD.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | Y | Y | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause a serious (even fatal) reaction called cytokine release syndrome-CRS. Careful monitoring and prompt treatment may decrease your risk. Before treatment with this medication, tell your doctor your medical history, especially of any current/recent infection.<br /><br />Tell your doctor right away if you have any symptoms of CRS such as high fever, difficulty breathing, chills/shaking chills, severe nausea/vomiting/diarrhea, severe muscle/joint pain, very low blood pressure, dizziness/lightheadedness. Serious nerve problems can occur after treatment with axicabtagene ciloleucel. Tell your doctor right away if you have trouble speaking and understanding, loss of balance, or mental/mood changes such as anxiety, confusion, memory loss.<br /><br /> For patients to receive this medication, all doctors, pharmacists, and patients must agree to, understand, and carefully follow the requirements of the Yescarta REMS Program. These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
| Diffuse large b-cell lymphoma | |
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
| 0-9 | A-Z |
|---|---|
| C83.3 | Diffuse large b-cell lymphoma |
| C83.30 | Diffuse large b-cell lymphoma, unspecified site |
| C83.31 | Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck |
| C83.32 | Diffuse large b-cell lymphoma, intrathoracic lymph nodes |
| C83.33 | Diffuse large b-cell lymphoma, intra-abdominal lymph nodes |
| C83.34 | Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.35 | Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.36 | Diffuse large b-cell lymphoma, intrapelvic lymph nodes |
| C83.37 | Diffuse large b-cell lymphoma, spleen |
| C83.38 | Diffuse large b-cell lymphoma, lymph nodes of multiple sites |
| C83.39 | Diffuse large b-cell lymphoma, extranodal and solid organ sites |
Formulary Reference Tool